Objective(s) Edoxaban, one factor Xa inhibitor, is a fresh oral anticoagulant that is developed instead of supplement K antagonists. In the mean time, paramount to notice that pooled outcomes other than the biggest trial demonstrated edoxaban was still connected with a reduction in the pace of main or medically relevant nonmajor blood loss event (p?=?0.02)… Continue reading Objective(s) Edoxaban, one factor Xa inhibitor, is a fresh oral anticoagulant